23 results on '"Indolfi, Ciro"'
Search Results
2. Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions
- Author
-
Montone, Rocco A., Rinaldi, Riccardo, Niccoli, Giampaolo, Andò, Giuseppe, Gragnano, Felice, Piccolo, Raffaele, Pelliccia, Francesco, Moscarella, Elisabetta, Zimarino, Marco, Fabris, Enrico, de Rosa, Salvatore, Calabrò, Paolo, Porto, Italo, Burzotta, Francesco, Grigioni, Francesco, Barbato, Emanuele, Chieffo, Alaide, Capodanno, Davide, Al-Lamee, Rasha, Ford, Tom J., Brugaletta, Salvatore, Indolfi, Ciro, Sinagra, Gianfranco, Perrone Filardi, Pasquale, and Crea, Filippo
- Published
- 2024
- Full Text
- View/download PDF
3. Incidence, Predictors, and Prognostic Impact of Neurologic Events After TAVR According to VARC-3 Criteria
- Author
-
Avvedimento, Marisa, Cepas-Guillén, Pedro, Garcia, Carla Benavent, Franzone, Anna, Sorrentino, Sabato, Indolfi, Ciro, Esposito, Giovanni, Mohammadi, Siamak, Pelletier-Beaumont, Emilie, and Rodés-Cabau, Josep
- Published
- 2024
- Full Text
- View/download PDF
4. Management of high and intermediate-high risk pulmonary embolism: A position paper of the Interventional Cardiology Working Group of the Italian Society of Cardiology
- Author
-
Andò, Giuseppe, Pelliccia, Francesco, Saia, Francesco, Tarantini, Giuseppe, Fraccaro, Chiara, D'Ascenzo, Fabrizio, Zimarino, Marco, Di Marino, Mario, Niccoli, Giampaolo, Porto, Italo, Calabrò, Paolo, Gragnano, Felice, De Rosa, Salvatore, Piccolo, Raffaele, Moscarella, Elisabetta, Fabris, Enrico, Montone, Rocco Antonio, Spaccarotella, Carmen, Indolfi, Ciro, Sinagra, Gianfranco, and Perrone Filardi, Pasquale
- Published
- 2024
- Full Text
- View/download PDF
5. COMPArison of Multi-Point Pacing and ConvenTional Cardiac Resynchronization Therapy Through Noninvasive Hemodynamics Measurement: Short- and Long-Term Results of the COMPACT-MPP Study
- Author
-
Passafaro, Francesco, Rapacciuolo, Antonio, Ruocco, Antonio, Ammirati, Giuseppe, Crispo, Salvatore, Pasceri, Eugenia, Santarpia, Giuseppe, Mauro, Ciro, Esposito, Giovanni, Indolfi, Ciro, and Curcio, Antonio
- Published
- 2024
- Full Text
- View/download PDF
6. Bempedoic acid: a new player for statin-intolerant patients and beyond
- Author
-
Giordano, Salvatore, Spaccarotella, Carmen Anna Maria, Esposito, Giovanni, and Indolfi, Ciro
- Published
- 2024
- Full Text
- View/download PDF
7. Application of the academic research consortium high bleeding risk criteria in patients treated with coronary bioresorbable polymer everolimus-eluting stents: Insights from the POEM trial
- Author
-
Rubbio, Antonio Popolo, primary, Testa, Luca, additional, Pivato, Carlo A., additional, Regazzoli, Damiano, additional, Piccolo, Raffaele, additional, Esposito, Giovanni, additional, Musto, Carmine, additional, Scalia, Lorenzo, additional, Pacchioni, Andrea, additional, Briguori, Carlo, additional, Lucisano, Luigi, additional, De Luca, Leonardo, additional, Conrotto, Federico, additional, Tartaglia, Francesco, additional, Latini, Alessia C., additional, Stankowski, Kamil, additional, Chiarito, Mauro, additional, Sardella, Gennaro, additional, Indolfi, Ciro, additional, Bedogni, Francesco, additional, Reimers, Bernhard, additional, Condorelli, Gianluigi, additional, and Stefanini, Giulio G., additional
- Published
- 2024
- Full Text
- View/download PDF
8. The Italian Fabry Disease Cardiovascular Registry (IFDCR)
- Author
-
Limongelli, Giuseppe, Biagini, Elena, Cappelli, Francesco, Graziani, Francesca, Monda, Emanuele, Olivotto, Iacopo, Parisi, Vanda, Pieroni, Maurizio, Rubino, Marta, Serratore, Serena, Sinagra, Gianfranco, Indolfi, Ciro, and Perrone Filardi, Pasquale
- Published
- 2024
- Full Text
- View/download PDF
9. One-month DAPT after biodegradable-polymer everolimus-eluting stent implantation in patients at high-bleeding risk: an individual patient data pooled analysis of the SENIOR and POEM trials.
- Author
-
Pivato, Carlo A, Stefanini, Giulio, Giacoppo, Daniele, Sideris, Georgios, Testa, Luca, Paunovic, Dragica, Briguori, Carlo, Indolfi, Ciro, Reimers, Bernhard, Sinnaeve, Peter, and Varenne, Olivier
- Subjects
DRUG-eluting stents ,MYOCARDIAL infarction ,PLATELET aggregation inhibitors ,DATA analysis ,CARDIOVASCULAR disease related mortality - Abstract
Aims Dual antiplatelet therapy (DAPT) can be shortened up to 1 month in high-bleeding risk (HBR) patients receiving a contemporary biodegradable-polymer sirolimus-eluting stent. We aimed to summarize the evidence on a similar DAPT regimen after biodegradable-polymer everolimus-eluting stent (EES) implantation in patients at HBR. Methods and results We pooled the individual participant data from the available trials evaluating this strategy, namely, the SENIOR and the POEM trials. Inclusion criteria were ≥1 biodegradable-polymer EES implantation and ≤1-month duration of DAPT. The primary endpoint was the 1-year composite of cardiovascular death, myocardial infarction, or stroke. Major bleeding was defined as Bleeding Academic Research Consortium (BARC) type 3–5 bleeding. Landmark analyses were performed at 1 month, the time point for intended DAPT interruption. We included 766 participants (age 77.5 ± 8.2 years, women 31.9%), 323 from the SENIOR and 443 from the POEM trial. The primary endpoint occurred in 45 participants (6.0%; 95% confidence interval [CI], 4.3–7.7%) through 1 year of follow-up, with 21 (2.8%; 95% CI, 1.6–3.9%) events during the first month and 24 (3.4%; 95% CI, 2.0–4.7%) thereafter. The incidences of cardiovascular death, myocardial infarction, and stroke were 2.2% (95% CI, 0.36–2.50%), 3.1% (95% CI, 1.8–4.3%), and 1.2% (95% CI, 0.4–2.0%), respectively. BARC type 3–5 bleeding ocuurred in 1.1% (95% CI, 0.3–1.8%) at 1 month and 2.9% (95% CI, 1.6–4.1%) at 1 year. Conclusion HBR patients receiving biodegradable-polymer EES had few ischemic and bleeding events when given 1 month of DAPT. One-month DAPT after biodegradable-polymer EES implantation seems safe in patients at HBR. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. The Role of Multimodality Imaging (CT & MR) as a Guide to the Management of Chronic Coronary Syndromes.
- Author
-
Tassetti, Luigi, Sfriso, Enrico, Torlone, Francesco, Baggiano, Andrea, Mushtaq, Saima, Cannata, Francesco, Del Torto, Alberico, Fazzari, Fabio, Fusini, Laura, Junod, Daniele, Maragna, Riccardo, Volpe, Alessandra, Carrabba, Nazario, Conte, Edoardo, Guglielmo, Marco, La Mura, Lucia, Pergola, Valeria, Pedrinelli, Roberto, Indolfi, Ciro, and Sinagra, Gianfranco
- Subjects
CARDIAC magnetic resonance imaging ,STRESS echocardiography ,MYOCARDIAL revascularization ,COMPUTED tomography ,REVASCULARIZATION (Surgery) - Abstract
Chronic coronary syndrome (CCS) is one of the leading cardiovascular causes of morbidity, mortality, and use of medical resources. After the introduction by international guidelines of the same level of recommendation to non-invasive imaging techniques in CCS evaluation, a large debate arose about the dilemma of choosing anatomical (with coronary computed tomography angiography (CCTA)) or functional imaging (with stress echocardiography (SE), cardiovascular magnetic resonance (CMR), or nuclear imaging techniques) as a first diagnostic evaluation. The determinant role of the atherosclerotic burden in defining cardiovascular risk and prognosis more than myocardial inducible ischemia has progressively increased the use of a first anatomical evaluation with CCTA in a wide range of pre-test probability in CCS patients. Functional testing holds importance, both because the role of revascularization in symptomatic patients with proven ischemia is well defined and because functional imaging, particularly with stress cardiac magnetic resonance (s-CMR), gives further prognostic information regarding LV function, detection of myocardial viability, and tissue characterization. Emerging techniques such as stress computed tomography perfusion (s-CTP) and fractional flow reserve derived from CT (FFRCT), combining anatomical and functional evaluation, appear capable of addressing the need for a single non-invasive examination, especially in patients with high risk or previous revascularization. Furthermore, CCTA in peri-procedural planning is promising to acquire greater importance in the non-invasive planning and guiding of complex coronary revascularization procedures, both by defining the correct strategy of interventional procedure and by improving patient selection. This review explores the different roles of non-invasive imaging techniques in managing CCS patients, also providing insights into preoperative planning for percutaneous or surgical myocardial revascularization. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Hypercholesterolemia and laboratory report: Joint document of the Italian Society of Cardiology (SIC) and the Italian Society of Clinical Biochemistry-Laboratory Medicine (SIBioC).
- Author
-
Graziani, Maria Stella, Paolillo, Stefania, Indolfi, Ciro, Zaninotto, Martina, Calabrò, Paolo, Ceriotti, Ferruccio, Barillà, Francesco, Clerico, Aldo, Ciccone, Marco Matteo, Trenti, Tommaso, Porto, Italo, Ciaccio, Marcello, Filardi, Pasquale Perrone, and Plebani, Mario
- Subjects
PATHOLOGICAL laboratories ,CLINICAL medicine ,HYPERCHOLESTEREMIA ,CLINICAL pathology ,CARDIOVASCULAR diseases risk factors ,LDL cholesterol ,LOW density lipoproteins - Abstract
Elevated plasma concentration of cholesterol bound to LDL (LDL-C) is the predominant risk factor for cardiovascular (CV) diseases. An important number of clinical trials demonstrated that the use of statins to reduce LDL-C is beneficial in terms of prevention of CV events in the entire population. Over time, specific LDL-C targets to be achieved have been established to guarantee the best outcome for the patient from the therapeutic intervention. The fundamental role of the clinical laboratory in diagnosis and treatment monitoring of dyslipidemias, requires that harmonization in the different phases of the laboratory process be pursued and achieved in order to allow the correct management of patients. The harmonization process has been the subject of national and international recommendations over time; however, a further recommendation is essential, considering that some recent evidences testify to a sub-optimal adoption of the indications by a non-negligible number of laboratories, confirming the need to repeat training and information activities. Aim of this joint document is to analyze the importance of the therapeutic targets to be achieved and the critical elements of laboratory diagnostic related to dyslipidemia, in order to provide indications for the harmonization of the reporting of the lipid profile. According to these recommendations, the lipid parameters should be reported accompanied by the therapeutic goals differentiated by the risk categories for LDL-C and non-HDL-C and by the threshold values for the other parameters. The use of comparison terms like Reference values or Normal values in the laboratory report must be definitely abandoned. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Pathophysiology of Atrial Fibrillation and Approach to Therapy in Subjects Less than 60 Years Old
- Author
-
Curcio, Antonio, primary, Scalise, Rosa, additional, and Indolfi, Ciro, additional
- Published
- 2024
- Full Text
- View/download PDF
13. An Artificial Intelligence Analysis of Electrocardiograms for the Clinical Diagnosis of Cardiovascular Diseases: A Narrative Review.
- Author
-
Di Costanzo, Assunta, Spaccarotella, Carmen Anna Maria, Esposito, Giovanni, and Indolfi, Ciro
- Subjects
ARTIFICIAL intelligence ,DIAGNOSIS ,CONVOLUTIONAL neural networks ,ARRHYTHMIA ,ACUTE coronary syndrome ,BRUGADA syndrome ,DEEP learning - Abstract
Artificial intelligence (AI) applied to cardiovascular disease (CVD) is enjoying great success in the field of scientific research. Electrocardiograms (ECGs) are the cornerstone form of examination in cardiology and are the most widely used diagnostic tool because they are widely available, inexpensive, and fast. Applications of AI to ECGs, especially deep learning (DL) methods using convolutional neural networks (CNNs), have been developed in many fields of cardiology in recent years. Deep learning methods provide valuable support for rapid ECG interpretation, demonstrating a diagnostic capability overlapping with specialists in the diagnosis of CVD by a classical analysis of macroscopic changes in the ECG trace. Through photoplethysmography, wearable devices can obtain single-derivative ECGs for the recognition of AI-diagnosed arrhythmias. In addition, CNNs have been developed that recognize no macroscopic electrocardiographic changes and can predict, from a 12-lead ECG, atrial fibrillation, even from sinus rhythm; left and right ventricular function; hypertrophic cardiomyopathy; acute coronary syndromes; or aortic stenosis. The fields of application are many, but numerous are the limitations, mainly associated with the reliability of the acquired data, an inability to verify black box processes, and medico-legal and ethical problems. The challenge of modern medicine is to recognize the limitations of AI and overcome them. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Commissural alignment during TAVR reduces the risk of overlap to coronary ostia
- Author
-
Carabetta, Nicole, Siller-Matula, Jolanta M., Boccuto, Fabiola, Panuccio, Giuseppe, Indolfi, Ciro, Torella, Daniele, and De Rosa, Salvatore
- Published
- 2024
- Full Text
- View/download PDF
15. Prof. Ciro Indol?: New Editor and Journal Vision.
- Author
-
Indolfi, Ciro
- Published
- 2024
- Full Text
- View/download PDF
16. [Hypercholesterolemia and laboratory reports: joint document from the Italian Society of Cardiology (SIC) and the Italian Society of Clinical Biochemistry and Clinical Molecular Biology - Lab Medicine (SIBioC)].
- Author
-
Paolillo S, Graziani MS, Indolfi C, Zaninotto M, Calabrò P, Ceriotti F, Barillà F, Clerico A, Ciccone MM, Trenti T, Porto I, Ciaccio M, Cesaro A, Fontanarosa S, Plebani M, and Perrone Filardi P
- Subjects
- Humans, Italy, Cardiovascular Diseases prevention & control, Societies, Medical, Cardiology, Cholesterol, LDL blood, Hypercholesterolemia
- Abstract
Dyslipidemia is one of the most important risk factors for the development of atherosclerotic disease and its control, through well-proven therapies, allows an optimal risk management over time. LDL-cholesterol targets are well defined by international guidelines and based on individual cardiovascular risk. As guidelines evolve, also laboratory reports need to do the same, including lipid reference values by cardiovascular risk classes, to avoid misunderstandings and inappropriate lipid-lowering therapy withdrawal. The aim of the present joint document from the Italian Society of Cardiology (SIC) and the Italian Society of Clinical Biochemistry and Clinical Molecular Biology - Lab Medicine (SIBioC) is to analyze the importance of cardiovascular risk estimation, therapeutical targets, and crucial elements about dyslipidemia in laboratory tests, as well as to suggest a shared proposal for the report of lipid profile parameters to be applied to all clinical scenarios of our daily practice.
- Published
- 2024
- Full Text
- View/download PDF
17. The Italian Fabry Disease Cardiovascular Registry (IFDCR).
- Author
-
Limongelli G, Biagini E, Cappelli F, Graziani F, Monda E, Olivotto I, Parisi V, Pieroni M, Rubino M, Serratore S, Sinagra G, Indolfi C, and Perrone Filardi P
- Subjects
- Humans, Italy epidemiology, Male, Female, Retrospective Studies, Prospective Studies, Adult, Middle Aged, Follow-Up Studies, Fabry Disease epidemiology, Fabry Disease genetics, Fabry Disease complications, Fabry Disease diagnosis, Fabry Disease therapy, Registries, Cardiovascular Diseases epidemiology
- Abstract
Aims: The Italian Fabry Disease Cardiovascular Registry (IFDCR) comprises 50 Italian centres with specific expertise in managing cardiovascular manifestations and complications of patients with Fabry disease (FD). The primary aim of the IFDCR is to examine and improve the clinical care and outcomes of patients with FD by addressing several knowledge gaps in the epidemiology, natural history, genotype-phenotype correlations, diagnosis, and management of this condition, with particular focus on cardiovascular manifestations and complications., Methods and Results: The IFDCR is an international, longitudinal, multicentre, non-interventional, observational study. Consecutive patients aged ≥2 years with a diagnosis of FD will be included in the study. The recruitment period consists of two parts: the retrospective enrolment period, from January 1981 to December 2023, and the prospective enrolment period, spanning from January 2024 to December 2031. The registry collects baseline and follow-up data, including the enrolment setting, patient demographics, family history, symptoms, clinical manifestations, electrocardiogram, cardiovascular imaging, laboratory assessment, medical therapy, genetic testing results, and outcomes., Conclusions: The IFDCR is a national, multicentre, registry that includes patients with FD. It holds detailed and multiparametric data across the patient pathway and clinical manifestations, acting as a powerful tool for improving the quality of care and conducting high-impact research., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
18. The clinical relevance of the reversal of coronary atherosclerotic plaque.
- Author
-
Cesaro A, Acerbo V, Indolfi C, Filardi PP, and Calabrò P
- Abstract
Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of death globally despite advances in preventive therapies. Understanding of the initiation and progression of atherosclerosis, the interplay between lipoproteins, endothelial dysfunction, inflammation, and immune responses is critical to treating this disease. The development of vulnerable coronary plaques prone to thrombosis, can lead to acute coronary syndromes, for these reasons, the potential plaque stabilization and regression through pharmacological interventions, particularly lipid-lowering agents like statins and PCSK9 inhibitors is crucial. The imaging techniques such as intravascular ultrasound (IVUS), near-infrared spectroscopy (NIRS), and optical coherence tomography (OCT) play a key role in assessing plaque composition and guiding interventional therapeutic strategies. Clinical evidence supports the efficacy of intensive lipid-lowering therapy in inducing plaque regression, with studies demonstrating reductions in plaque volume and improvements in plaque morphology assessed by IVUS, OCT and NIRS. While pharmacological interventions show promise in promoting plaque regression and stabilization, their impact on long-term cardiovascular events requires further investigation. Multimodality imaging and comprehensive outcome trials are proposed as essential tools for elucidating the relationship between plaque modification and clinical benefit in coronary atherosclerosis. The stabilization or regression of atherosclerotic plaque might serve as the phenomenon linking the reduction in LDL-C levels to the decrease in cardiovascular events. Overall, this review emphasizes the ongoing efforts to advance our understanding of ASCVD pathophysiology and optimize therapeutic approaches for improving patient outcomes., Competing Interests: Declaration of competing interests The authors declare they have no conflict of interest., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
19. [SIC Position paper: Treat to prevent the first event - intensive LDL cholesterol lowering in patients at very high cardiovascular risk without a previous cardiovascular event. From ESC guidelines to clinical practice].
- Author
-
Perrone Filardi P, Nardi E, Agostoni P, Barillà F, Calabrò P, Ciccone MM, Curcio A, Indolfi C, Muscoli S, Nodari S, Paolillo S, Patti G, Porto I, Sinagra G, Gallo L, Fontanarosa S, Vizza CD, and Gargiulo P
- Subjects
- Humans, Practice Guidelines as Topic, Italy, Secondary Prevention methods, Europe, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage, Hypercholesterolemia complications, Hypercholesterolemia drug therapy, Cardiovascular Diseases prevention & control, Cardiovascular Diseases etiology, Cholesterol, LDL blood, Heart Disease Risk Factors
- Abstract
Cardiovascular (CV) diseases account for over 4 million deaths every year in Europe and over 220 000 deaths in Italy, representing the leading cause of morbidity and mortality worldwide. The European Society of Cardiology (ESC) guidelines have visionary included in the at very high CV risk group patients without previous acute ischemic events, such as those with subclinical atherosclerosis, chronic coronary syndrome or peripheral arterial disease, familial hypercholesterolemia, diabetes mellitus with target organ damage or multiple associated risk factors, and those with high calculated CV risk score, recommending to consider them and to achieve the same LDL-cholesterol targets as for secondary prevention patients. The aim of this position paper is to provide an updated overview of ESC guidelines that focuses on these patient categories to raise awareness within the clinical community regarding CV risk reduction in this specific epidemiological context.
- Published
- 2024
- Full Text
- View/download PDF
20. Strike early-strike strong lipid-lowering strategy with PCSK9i in ACS patients. Real-world evidence from AT-TARGET-IT registry.
- Author
-
Gargiulo P, Basile C, Galasso G, Bellino M, D'Elia D, Patti G, Bosco M, Prinetti M, Andò G, Campanella F, Taverna G, Calabrò P, Cesaro A, Fimiani F, Catalano A, Varbella F, Corleto A, Barillà F, Muscoli S, Musumeci G, Delnevo F, Giallauria F, Napoli R, Porto I, Polimeni A, Quarta R, Maloberti A, Merlini PA, De Luca L, Casu G, Brunetti ND, Crisci M, Paloscia L, Bilato C, Indolfi C, Marzano F, Fontanarosa S, Buonocore D, Parlati ALM, Nardi E, Prastaro M, Soricelli A, Salvatore M, Paolillo S, and Perrone-Filardi P
- Abstract
Aims: No data are available on early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in patients with acute coronary syndrome (ACS) in real-world. This study investigates the effects of PCSK9i started at time of ACS hospitalization on lipid control and major CV events in real-world., Methods: The lipid control outcome was the percentage of patients reaching the LDL-C target of < 55 mg/dL at first lipid control. The clinical outcome was the incidence of composite major CV events (all cause death, non-fatal MI, non-fatal stroke, and ischemia-driven revascularization) during follow-up in relation to quartiles of LDL-C at first lipid control., Results: We included 771 patients with ACS from AT-TARGET-IT registry, receiving PCSK9i prescription during hospitalization or at discharge. Median LDL-C was 137 mg/dL and decreased to 43 mg/dL at first lipid control. 527 (68.3%) patients achieved LDL-C target at the first lipid control at a median time of 37 days from hospitalization; of them, 404 (76.8%) were discharged on statin plus ezetimibe background therapy. Event curves through a median follow-up of 11 months across quartiles of LDL-C showed a stepwise lower risk of 4P-MACE, 3P-MACE, all-cause mortality, and ischemia-driven revascularization in lower quartile of LDL-C values at first lipid control (<23 mg/dL) and in patients reaching LDL-C <55 mg/dL., Conclusions: Intensive and early lipid-lowering therapy using PCSK9i in patients with ACS (strike early strike strong strategy) is safe and effective in clinical practice and associated with a reduction of residual CV risk., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
21. Risk Score for Prediction of Dialysis After Transcatheter Aortic Valve Replacement.
- Author
-
Pasceri V, Pelliccia F, Mehran R, Dangas G, Porto I, Radico F, Biancari F, D'Ascenzo F, Saia F, Luzi G, Bedogni F, Amat Santos IJ, De Marzo V, Dimagli A, Mäkikallio T, Stabile E, Blasco-Turrión S, Testa L, Barbanti M, Tamburino C, Fabiocchi F, Chilmeran A, Conrotto F, Costa G, Stefanini G, Spaccarotella C, Macchione A, La Torre M, Bendandi F, Juvonen T, Wańha W, Wojakowski W, Benedetto U, Indolfi C, Hildick-Smith D, and Zimarino M
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Aortic Valve surgery, Registries, Renal Dialysis, Risk Factors, Treatment Outcome, Multicenter Studies as Topic, Aortic Valve Stenosis surgery, Diabetes Mellitus, Transcatheter Aortic Valve Replacement adverse effects
- Abstract
Background: Dialysis is a rare but serious complication after transcatheter aortic valve replacement. We analyzed the large multicenter TRITAVI (transfusion requirements in transcatheter aortic valve implantation) registry in order to develop and validate a clinical score assessing this risk., Methods and Results: A total of 10 071 consecutive patients were enrolled in 19 European centers. Patients were randomly assigned (2:1) to a derivation and validation cohort. Two scores were developed, 1 including only preprocedural variables (TRITAVIpre) and 1 also including procedural variables (TRITAVIpost). In the 6714 patients of the derivation cohort (age 82±6 years, 48% men), preprocedural factors independently associated with dialysis and included in the TRITAVIpre score were male sex, diabetes, prior coronary artery bypass graft, anemia, nonfemoral access, and creatinine clearance <30 mL/min per m
2 . Additional independent predictors among procedural features were volume of contrast, need for transfusion, and major vascular complications. Both scores showed a good discrimination power for identifying risk for dialysis with C-statistic 0.78 for TRITAVIpre and C-statistic 0.88 for TRITAVIpost score. Need for dialysis increased from the lowest to the highest of 3 risk score groups (from 0.3% to 3.9% for TRITAVIpre score and from 0.1% to 6.2% for TRITAVIpost score). Analysis of the 3357 patients of the validation cohort (age 82±7 years, 48% men) confirmed the good discrimination power of both scores (C-statistic 0.80 for TRITAVIpre and 0.81 for TRITAVIpost score). Need for dialysis was associated with a significant increase in 1-year mortality (from 6.9% to 54.4%; P =0.0001)., Conclusions: A simple preprocedural clinical score can help predict the risk of dialysis after transcatheter aortic valve replacement.- Published
- 2024
- Full Text
- View/download PDF
22. [ANMCO/SIC Consensus statement on pulmonary arterial hypertension].
- Author
-
Vatrano M, Manzi G, Picariello C, D'Alto M, Enea I, Ghio S, Caravita S, Argiento P, Garascia A, Vitulo P, Gabrielli D, Agostoni P, Corda M, Sinagra G, Grimaldi M, Scelsi L, Badagliacca R, D'Agostino C, Perrone Filardi P, Colivicchi F, Indolfi C, Roncon L, Galiè N, Oliva F, and Vizza CD
- Subjects
- Humans, Pulmonary Arterial Hypertension, Cardiology, Hypertension, Pulmonary therapy, Hypertension, Pulmonary drug therapy, Cardiovascular System, Ventricular Dysfunction, Right
- Abstract
Pulmonary hypertension (PH) is a frequent pathological condition worldwide, mainly secondary to cardiovascular and respiratory diseases, with a poor prognosis. Pulmonary arterial hypertension (PAH) is a rare form that affects the arterial pulmonary vasculature. PH and PAH are characterized by non-specific symptoms and a progressive increase of pulmonary vascular resistance that results in progressive, sometimes irreversible, right ventricular dysfunction. In recent years, a growing medical and social commitment on this disease allowed more accurate diagnosis in shorter times. However, the gap between guidelines and clinical practice remains a challenge for all medical doctors involved in the disease management. Considering the needs to share and describe diagnostic and therapeutic pathways, to measure the results obtained and to address the economical and organizational problems of this disease, all involved figures should collaborate to improve its prognostic impact and health expenses. In this consensus document, the PH experts of the Italian Association of Hospital Cardiologists (ANMCO) together with those of the Italian Society of Cardiology (SIC), address 1) definition, classification and unmet needs of PH and PAH; 2) classification and characteristics of centers involved in the diagnosis and treatment of the disease; 3) proposal of organization of a diagnostic-therapeutic pathway, based on robust and recent scientific evidence.
- Published
- 2024
- Full Text
- View/download PDF
23. Strategies to Minimize Access Site-related Complications in Patients Undergoing Transfemoral Artery Procedures with Large-bore Devices.
- Author
-
Sorrentino S, Di Costanzo A, Salerno N, Caracciolo A, Bruno F, Panarello A, Bellantoni A, Mongiardo A, and Indolfi C
- Subjects
- Humans, Risk Factors, Vascular Closure Devices, Endovascular Procedures adverse effects, Endovascular Procedures instrumentation, Treatment Outcome, Hemostatic Techniques instrumentation, Hemostatic Techniques adverse effects, Vascular Access Devices adverse effects, Equipment Design, Risk Assessment, Femoral Artery, Hemorrhage prevention & control, Hemorrhage etiology, Catheterization, Peripheral adverse effects, Catheterization, Peripheral instrumentation, Punctures
- Abstract
Large bore accesses refer to accesses with a diameter of 10 French or greater and are necessary for various medical devices, including those used in transcatheter aortic valve replacement, endovascular aneurysm repair stent-grafts, and percutaneous mechanical support devices. Notably, the utilization of these devices via femoral access is steadily increasing due to advancements in technology and implantation techniques, which are expanding the pool of patients suitable for percutaneous procedures. However, procedures involving large bore devices carry a high risk of bleeding and vascular complications (VCs), impacting both morbidity and long-term mortality. In this review article, we will first discuss the incidence, determinants, and prognostic impact of VCs in patients undergoing large bore access procedures. Subsequently, we will explore the strategies developed in recent years to minimize VCs, including techniques for optimizing vascular puncture through femoral cannulation, such as the use of echo-guided access cannulation and fluoroscopic guidance. Additionally, we will evaluate existing vascular closure devices designed for large bore devices. Finally, we will consider new pharmacological strategies aimed at reducing the risk of periprocedural access-related bleeding., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.